Hospital Profile
Name | Mayo Clinic Health System - Waseca |
---|
Type | Critical Access Hospital |
---|
Location | 501 North State Street, Waseca, Minnesota |
---|
Ownership | Voluntary non-profit - Private |
---|
Emergency Services | Yes |
---|
Medicare ID (CCN) | 241345 |
Patients' Experience Survey:
Willingness to Recommend Hospital:
Yes Patients who reported YES, they would definitely recommend the hospital
Probably Patients who reported YES, they would probably recommend the hospital
No Patients who reported NO, they would probably not or definitely not recommend the hospital
Cleanliness of Hospital Environment:
Always Patients who reported that their room and bathroom were "Always" clean
Usually Patients who reported that their room and bathroom were "Usually" clean
Sometimes or Never Patients who reported that their room and bathroom were "Sometimes" or "Never" clean
Quietness of Hospital Environment:
Always Patients who reported that the area around their room was "Always" quiet at night
Usually Patients who reported that the area around their room was "Usually" quiet at night
Sometimes or Never Patients who reported that the area around their room was "Sometimes" or "Never" quiet at night
Always Patients who reported that their nurses "Always" communicated well
Usually Patients who reported that their nurses "Usually" communicated well
Sometimes or Never Patients who reported that their nurses "Sometimes" or "Never" communicated well
Always Patients who reported that their doctors "Always" communicated well
Usually Patients who reported that their doctors "Usually" communicated well
Sometimes or Never Patients who reported that their doctors "Sometimes" or "Never" communicated well
Responsiveness of Hospital Staff:
Always Patients who reported that they "Always" received help as soon as they wanted
Usually Patients who reported that they "Usually" received help as soon as they wanted
Sometimes or Never Patients who reported that they "Sometimes" or "Never" received help as soon as they wanted
Communication about Medicines:
Always Patients who reported that staff "Always" explained about medicines before giving it to them
Usually Patients who reported that staff "Usually" explained about medicines before giving it to them
Sometimes or Never Patients who reported that staff "Sometimes" or "Never" explained about medicines before giving it to them
Yes Patients who reported that YES, they were given information about what to do during their recovery at home
No Patients who reported that NO, they were not given information about what to do during their recovery at home
Always Patients who "Strongly Agree" they understood their care when they left the hospital
Usually Patients who “Agree” they understood their care when they left the hospital
Sometimes or Never Patients who “Disagree” or “Strongly Disagree” they understood their care when they left the hospital
NPI Associated with the Hospital:
Unlike individual providers, Hospitals may have multiple NPI numbers for example, there can be a separate NPI for each unit within the hospital. We have found possible NPI number/s associated with Mayo Clinic Health System - Waseca from NPPES records by matching pattern on the basis of name, address, phone number etc. Please use this information accordingly.
NPI Number | 1740256668 |
Organization Name | MAYO CLINIC HEALTH SYSTEM-SOUTHWEST MINNESOTA REGION |
Doing Business As | MAYO CLINIC HEALTH SYSTEM-WASECA |
Address | 501 North State Street, Waseca, MN 56093 |
Hospital Type | General Acute Care Hospital - Critical Access |
Phone Number | 507-835-1210 |
News Archive
XOMA receives final $2.0 million from Kaketsuken under antibody technology collaboration
XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, today announced receipt of the final $2.0 million payment from Kaketsuken under the $8.0 million collaboration announced in November 2009. The agreement involves multiple proprietary XOMA antibody research and development technologies, including a new XOMA phage display library, and a suite of integrated information and data management systems.
Sanofi, TB Alliance form research collaboration to search for new treatment compounds
French drug maker Sanofi on Thursday announced a new three-year research collaboration agreement with the TB Alliance "to accelerate the discovery and development of novel compounds against tuberculosis," RTTNews reports.
FXR can slow proliferation of tamoxifen-resistant breast cancer cells: Study
A receptor that is present in the nucleus of cells can, when activated, slow the growth of tamoxifen-resistant breast cancer cells, a new study found. The study built on the recent discovery that farnesoid X receptor — a nuclear receptor found mainly in the liver — is found in breast cancer tissue.
NSF awards grants to advance Ebola research
The National Science Foundation has awarded the first of a number of rapid response grants to advance fundamental Ebola research.
Read more Medical News
› Verified 9 days ago
Structural Quality Measures:
Able to receive lab results electronically | Yes |
Able to track patients' lab results, tests, and referrals electronically between visits | Yes |
News Archive
XOMA receives final $2.0 million from Kaketsuken under antibody technology collaboration
XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, today announced receipt of the final $2.0 million payment from Kaketsuken under the $8.0 million collaboration announced in November 2009. The agreement involves multiple proprietary XOMA antibody research and development technologies, including a new XOMA phage display library, and a suite of integrated information and data management systems.
Sanofi, TB Alliance form research collaboration to search for new treatment compounds
French drug maker Sanofi on Thursday announced a new three-year research collaboration agreement with the TB Alliance "to accelerate the discovery and development of novel compounds against tuberculosis," RTTNews reports.
FXR can slow proliferation of tamoxifen-resistant breast cancer cells: Study
A receptor that is present in the nucleus of cells can, when activated, slow the growth of tamoxifen-resistant breast cancer cells, a new study found. The study built on the recent discovery that farnesoid X receptor — a nuclear receptor found mainly in the liver — is found in breast cancer tissue.
NSF awards grants to advance Ebola research
The National Science Foundation has awarded the first of a number of rapid response grants to advance fundamental Ebola research.
Read more News
› Verified 9 days ago